SGCG and neoplasm: Dollinger et al. [31] compared in a preclinical case cohort study a combined DNA stool assay [ColoAlert® combined with a gFOBT and an hDNA quantification test (threshold 15 ng/μL)] with a single gFOBT (ColoScreen-ES®, Helena Biosciences), a single tumour Pyruvate Kinase Isoenzyme Type M2 (M2-PK) test (ScheBo Biotech AG) and a combined gFOBT/M2-PK assay.